With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...
AstraZeneca Plc has strong compliance policies in China and is working closely with authorities following the detention of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback